Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen, Silicon Genetics, Gene Logic, Affymetrix, DNAPrint


Nanogen has released a multiplex analyte specific reagent for the detection of Factor V Leiden and Factor II prothrombin gene mutations. The company said CLIA-certified laboratories can use the reagents to create and validate tests that detect these mutations.

The ASR for Factor V/Factor II prothrombin covers mutations tied to cardiovascular disease and thrombosis, respectively, and comprises reagents, controls, and analysis of the G1691A mutation on the Factor V gene and the G20210A mutation on the prothrombin gene, according to Nanogen.

Nanogen last week also released its Assay ToolBox, which includes a set of consumable products that allows researchers to use Nanogen’s NanoChip platform to “facilitate their own” protocol and assay development.

Silicon Genetics has released new versions of its flagship GeneSpring and GeNet products.

The tools, which are used to analyze and manage expression data, “have been updated to facilitate automation and increase the efficiency of high throughput data analysis in genomics research organizations,” Silicon Genetics said last week.

“With the new releases of GeneSpring 5.1 and GeNet 3.1, we are bringing new levels of scala-bility and automation to expression analysis,” the company said.

Gene Logic has expanded its ToxExpress toxicogenomics product line with the launch of its Molecular Mechanism of Toxicity services. In the new service, Gene Logic will study candidate drugs submitted by customers to determine how and why certain observed or anticipated toxicities arise.

The service, called ToxMOT for short, can enable researchers to “determine molecular mechanisms being triggered by toxicity; understand biological changes following adverse events; confirm observations or suspicions of toxicity; and facilitate drug-development decisions by ranking compounds based on their mechanism of toxicity,” Gene Logic said in a statement.

Affymetrix has begun taking orders for new versions of its mouse and rat expression arrays, the GeneChip Mouse Expression Set 430 and the GeneChip Rat Expression Set 230. The products represent the “most comprehensive … and up-to-date versions of public domain rat and mouse genome information available on a microarray platform,” Affymetrix said. The company expects to begin shipping the new array sets by the end of the month.

DNAPrint plans to collaborate with GeneLink to develop genetic tests for personalized cosmetics, the company said last week.

The firms will develop tests designed to assess the genetic risk for certain common skin deficiencies. Based on results of such tests, health- care professionals may recommend skin-care products that might compensate for these deficiencies.

Specifically, the tests would be offered as part of precautionary recommendations for certain dermatological problems, and offered to the cosmetics and personal-care industry.

DNAPrint, based in Sarasota, Fla., brings to the collaboration its genotyping technology while GeneLink will make use of existing tests and methods.

Both companies intend to screen millions of candidate genetic markers, they said.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.